Cardiovascular disease (CVD) is a leading cause of death worldwide. CVD includes conditions such as myocardial infarction (MI), arrhythmias, valvular heart disease, and cardiomyopathy. The limitations of heart treatment are related to the inability of damaged cells to regenerate, which leads to an increasing demand for new therapies. Cardiac tissue engineering (CTE) aims to efficiently regenerate damaged cardiac tissues by combining cells and biomaterials to address these diseases. Various cell types have been used in CTE research, including adult and pluripotent stem cells, the latter differentiating into functional cardiomyocytes. An ideal biomaterial promotes efficient adhesion, growth, and differentiation of cardiac cells and possesses the appropriate characteristics needed for functional cardiac cells, showing great potential for heart repair and regeneration. This review focuses on various tissue engineering approaches for the regeneration and repair of cardiac tissues following myocardial infarction.
GopinathannairRCornwellWKDukesJW, et al. Device therapy and arrhythmia management in left ventricular assist device recipients: a scientific statement from the american heart association. Circulation2019; 139(20): e967–e989.
2.
SamskyMDMorrowDAProudfootAG, et al. Cardiogenic shock after acute myocardial infarction: a review. JAMA2021; 326(18): 1840–1850.
3.
PeichlPBayes-GenisADenekeT, et al. Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC. Europace2024; 26(11): euae272.
4.
LarsenPMTeerlinkJR. Team-based care for patients hospitalized with heart failure. Heart Fail Clin2015; 11: 359–370.
5.
TakahashiKYamanakaS. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell2006; 126: 663–676.
6.
IshigamiMMasumotoHIkunoT, et al. Human iPS cell-derived cardiac tissue sheets for functional restoration of infarcted porcine hearts. PLoS One2018; 13: e0201650.
7.
IvashchenkoCYPipesGCLozinskayaIM, et al. Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype. Am J Physiol Heart Circ Physiol2013; 305: H913–H922.
8.
OdukYZhuWKannappanR, et al. VEGF nanoparticles repair the heart after myocardial infarction. Am J Physiol Heart Circ Physiol2018; 314: H278–H284.
9.
WuPSaiXLiZ, et al. Maturation of induced pluripotent stem cell-derived cardiomyocytes and its therapeutic effect on myocardial infarction in mouse. Bioact Mater2022; 20: 286–305.
10.
BahardoustMBaghoi-HosseinabadiZ. Role of adipose-derived mesenchymal stem cells in the regeneration of cardiac tissue and improvement of cardiac function: a narrative review. Biointerface Res Appl Chem2021; 11: 8446–8456.
11.
MenaschéPAlfieriOJanssensS, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation2008; 117(9): 1189–1200.
12.
PatelANHenryTDQuyyumiAA, et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet2016; 387(10036): 2412–2421.
13.
MenaschéPVanneauxVHagègeA, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J Am Coll Cardiol2018; 71(4): 429–438.
14.
HuangKOzpinarEWSuT, et al. An off-the-shelf artificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs. Sci Transl Med2020; 12(538): eaat9683.
15.
WagnerMJKhanMMohsinS. Healing the broken heart; the immunomodulatory effects of stem cell therapy. Front Immunol2020; 11: 639.
16.
YanWXiaYZhaoH, et al. Stem cell-based therapy in cardiac repair after myocardial infarction: promise, challenges, and future directions. J Mol Cell Cardiol2024; 188: 1–14.
17.
Pascual-GilSGarbayoEDíaz-HerráezP, et al. Heart regeneration after myocardial infarction using synthetic biomaterials. J Control Release2015; 203: 23–38.
18.
AugustineRDanPHasanA, et al. Stem cell-based approaches in cardiac tissue engineering: controlling the microenvironment for autologous cells. Biomed Pharmacother2021; 138: 111425.
19.
McMahanSTaylorACopelandKM, et al. Current advances in biodegradable synthetic polymer based cardiac patches. J Biomed Mater Res A2020; 108(4): 972–983.
20.
ZhangYMuWZhangY, et al. Recent advances in cardiac patches: materials, preparations, and properties. ACS Biomater Sci Eng2022; 8(9): 3659–3675.
21.
ZimmermannWHMelnychenkoIEschenhagenT. Engineered heart tissue for regeneration of diseased hearts. Biomaterials2004; 25(9): 1639–1647.
22.
RuvinovECohenS. Alginate biomaterial for the treatment of myocardial in farction: progress, translational strategies, and clinical outlook: from ocean algae to patient bedside. Adv Drug Deliv Rev2016; 96: 54–76.
23.
ChenJZhanYWangY, et al. Chitosan/silk fibroin modified nanofibrous patches with mesenchymal stem cells prevent heart remodeling post-myocardial infarction in rats. Acta Biomater2018; 80: 154–168.
24.
PokSBenavidesOMHallalP, et al. Use of myocardial matrix in a chitosan-based full-thickness heart patch. Tissue Eng Part A2014; 20: 1877–1887.
25.
KapnisiMMansfieldCMarijonC, et al. Auxetic cardiac patches with tunable mechanical and conductive properties toward treating myocardial infarction. Adv Funct Mater2018; 28: 1800618.
26.
LiuZWangHWangY, et al. The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment. Biomaterials2012; 33(11): 3093–3106.
27.
ZhangJLiJQuX, et al. Development of composite functional tissue sheets using hiPSC-CMs and hADSCs to improve the cardiac function after myocardial infarction. Bioact Mater2024; 37: 533–548.
28.
LakshmananRKrishnanUMSethuramanS. Polymeric scaffold aided stem cell therapeutics for cardiac muscle repair and regeneration. Macromol Biosci2013; 13(9): 1119–1134.
29.
ZammarettiPJaconiM. Cardiac tissue engineering: regeneration of the wounded heart. Curr Opin Biotechnol2004; 15(5): 430–434.
30.
LamMTWuJC. Biomaterial applications in cardiovascular tissue repair and regeneration. Expert Rev Cardiovasc Ther2012; 10(8): 1039–1049.
31.
MiyagiYChiuLLCiminiM, et al. Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials2011; 32(5): 1280–1290.
32.
TakadaTSasakiDMatsuuraK, et al. Aligned human induced pluripotent stem cell-derived cardiac tissue improves contractile properties through promoting unidirectional and synchronous cardiomyocyte contraction. Biomaterials2022; 281: 121351.
33.
MiyagawaSKawamuraTItoE, et al. Pre-clinical evaluation of the efficacy and safety of human induced pluripotent stem cell-derived cardiomyocyte patch. Stem Cell Res Ther2024; 15(1): 73.
34.
WendelJSYeLTaoR, et al. Functional effects of a tissue-engineered cardiac patch from human induced pluripotent stem cell-derived cardiomyocytes in a rat infarct model. Stem Cells Transl Med2015; 4(11): 1324–1332.
35.
LiJQuXLiuL, et al. Developing thick cardiac tissue with a multilayer fiber sheet for treating myocardial infarction. Adv Fiber Mater2023; 5: 1905–1918.
36.
PetersenTHCalleEAZhaoL, et al. Tissue-engineered lungs for in vivo implantation. Science2010; 329(5991): 538–541.
37.
UygunBESoto-GutierrezAYagiH, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med2010; 16(7): 814–820.
38.
NishimuraY. Current status and future prospects of decellularized kidney tissue. J Artif Organs2023; 26(3): 171–175.
39.
AgmonGChristmanKL. Controlling stem cell behavior with decellularized extracellular matrix scaffolds. Curr Opin Solid State Mater Sci2016; 20(4): 193–201.
40.
CrapoPMGilbertTWBadylakSF. An overview of tissue and whole organ decellularization processes. Biomaterials2011; 32(12): 3233–3243.
41.
TaylorDASampaioLCFerdousZ, et al. Decellularized matrices in regenerative medicine. Acta Biomater2018; 74: 74–89.
42.
OttHCMatthiesenTSGohSK, et al. Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart. Nat Med2008; 14(2): 213–221.
43.
OberwallnerBBrodaracAChoiYH, et al. Preparation of cardiac extracellular matrix scaffolds by decellularization of human myocardium. J Biomed Mater Res A2014; 102(9): 3263–3272.
44.
KeaneTJSwinehartITBadylakSF. Methods of tissue decellularization used for preparation of biologic scaffolds and in vivo relevance. Methods2015; 84: 25–34.
45.
GuyetteJPCharestJMMillsRW, et al. Bioengineering human myocardium on native extracellular matrix. Circ Res2016; 118(1): 56–72.
46.
TaylorDAFrazierOHElgaladA, et al. Building a total bioartificial heart: harnessing nature to overcome the current hurdles. Artif Organs2018; 42(10): 970–982.
47.
KitaharaHYagiHTajimaK A, et al. Heterotopic transplantation of a decellularized and recellularized whole porcine heart. Interact Cardiovasc Thorac Surg2016; 22(5): 571–579.
48.
BelvisoIRomanoVSaccoAM, et al. Decellularized human dermal matrix as a biological scaffold for cardiac repair and regeneration. Front Bioeng Biotechnol2020; 8: 229.
49.
JiangYSunSJZhenZ, et al. Myocardial repair of bioengineered cardiac patches with decellularized placental scaffold and human-induced pluripotent stem cells in a rat model of myocardial infarction. Stem Cell Res Ther2021; 12(1): 13.
50.
Arenas-HerreraJEKoIKAtalaA, et al. Decellularization for whole organ bioengineering. Biomed Mater2013; 8(1): 014106.
51.
ZhangJWilsonGFSoerensAG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res2009; 104: e30–e41.
52.
FreundCMummeryCL. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J Cell Biochem2009; 107(4): 592–599.
53.
SekiTYuasaSKusumotoD, et al. Generation and characterization of functional cardiomyocytes derived from human T cell-derived induced pluripotent stem cells. PLoS One2014; 9(1): e85645.
54.
HuangYWangTLópezMEU, et al. Recent advancements of human iPSC derived cardiomyocytes in drug screening and tissue regeneration. Microphysiol Syst2020; 4: 2.
55.
FunakoshiSYoshidaY. Recent progress of iPSC technology in cardiac diseases. Arch Toxicol2021; 95(12): 3633–3650.
56.
IedaMFuJDDelgado-OlguinP, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell2010; 142(3): 375–386.
57.
Nakanishi-KoakutsuMMikiKNakaY, et al. CD151 expression marks atrial- and ventricular- differentiation from human induced pluripotent stem cells. Commun Biol2024; 7(1): 231.
58.
NattasitPNiibeKYamadaM, et al. Stiffness-tunable hydrogel-sandwich culture modulates the YAP-mediated mechanoresponse in induced-pluripotent stem cell embryoid bodies and augments cardiomyocyte differentiation. Macromol Biosci2023; 23(7): e2300021.
59.
IwońZKrogulecETarnowskaI, et al. Maturation of human cardiomyocytes derived from induced pluripotent stem cells (iPSC-CMs) on polycaprolactone and polyurethane nanofibrous mats. Sci Rep2024; 14(1): 12975.
60.
KobayashiHTohyamaSIchimuraH, et al. Regeneration of nonhuman primate hearts with human induced pluripotent stem cell-derived cardiac spheroids. Circulation2024; 150(8): 611–621.
61.
CarvalhoT. Stem cell-derived heart cells injected into first patient. Nat Med2023; 29(5): 1030–1031.
62.
KurodaYIidaJMurataK, et al. Transplantation of vascularized cardiac microtissue from human induced pluripotent stem cell cells improves impaired electrical conduction in a porcine myocardial injury model. JTCVS Open2025.25:154–162
63.
MizukamiYAbeTShibataH, et al. MHC-matched induced pluripotent stem cells can attenuate cellular and humoral immune responses but are still susceptible to innate immunity in pigs. PLoS One2014; 9(6): e98319.
64.
MurataKIkegawaMMinatoyaK, et al. Strategies for immune regulation in iPS cell-based cardiac regenerative medicine. Inflamm Regen2020; 40: 36.
65.
FarboudSPFathiEValipourB, et al. Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges. J Transl Med2024; 22(1): 783.
66.
GaoLKupferMEJungJP, et al. Myocardial tissue engineering with cells derived from human-induced pluripotent stem cells and a native-like, high-resolution, 3-dimensionally printed scaffold. Circ Res2017; 120(8): 1318–1325.
67.
BettiniACamellitiPStuckeyDJ, et al. Injectable biodegradable microcarriers for iPSC expansion and cardiomyocyte differentiation. Adv Sci2024; 11(32): e2404355.
68.
Scafa UdrișteANiculescuAGIliuțăL, et al. Progress in biomaterials for cardiac tissue engineering and regeneration. Polymers2023; 15(5): 1177.
69.
AhrensJHUzelSGMSkylar-ScottM, et al. Programming cellular alignment in engineered cardiac tissue via bioprinting anisotropic organ building blocks. Adv Mater2022; 34(26): e2200217.
70.
LeeJRSimW-SParkHJ, et al. Targeted delivery of apoptotic cell-derived nanovesicles prevents cardiac remodeling and attenuates cardiac function exacerbation. Adv Funct Mater2023; 33: 2210864.
71.
KobayashiHTohyamaSKanazawaH, et al. Intracoronary transplantation of pluripotent stem cell-derived cardiomyocytes: Inefficient procedure for cardiac regeneration. J Mol Cell Cardiol2023; 174: 77–87.
